Efficacy and safety of radioimmuno-therapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
| Autor: | Leo I. Gordon, Mary Beth Riley |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
medicine.medical_specialty Yttrium-90 Ibritumomab Tiuxetan Lymphoma B-Cell medicine.medical_treatment Population Ibritumomab tiuxetan Antineoplastic Agents Nursing Methodology Research Patient Education as Topic Internal medicine medicine Humans Yttrium Radioisotopes education Adverse effect CD20 education.field_of_study biology Oncology (nursing) business.industry Oncology Nursing Antibodies Monoclonal Dose-Response Relationship Radiation Radiotherapy Dosage Radioimmunotherapy Antigens CD20 Clinical trial Regimen biology.protein Controlled Clinical Trials as Topic business medicine.drug |
| Zdroj: | Seminars in Oncology Nursing. 20:8-13 |
| ISSN: | 0749-2081 |
| Popis: | Objectives To detail recent developments pertaining to the efficacy and safety of radioimmunotherapy with yttrium 90 ( 90 Y) ibritumomab tiuxetan for patients with B-cell non-Hodgkin’s lymphoma (NHL). Data sources Published clinical trials of 90 Y ibritumomab tiuxetan and secondary literature on radioimmunotherapy and NHL. Conclusion Yttrium 90 ibritumomab tiuxetan is safe and effective in the indicated population. It has a good safety profile and is generally well tolerated. It is not associated with the adverse events from conventional chemotherapy and external beam radiation therapy. Implications for nursing practice Nursing professionals who are aware of the efficacy and safety data associated with 90 Y ibritumomab tiuxetan can optimize efficacy and educate patients and their caregivers about the regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect